期刊文献+

胃癌组织ABCG2和P-gp蛋白表达及其临床意义分析 被引量:11

Expressions and clinical significance of ABCG2 and P-gp protein in gastric carcinoma tissues
原文传递
导出
摘要 目的:探讨中晚期胃癌组织中ABCG2和P-gp蛋白的表达及其临床意义。方法:采用免疫组化法检测60例中晚期胃癌组织和对应的癌旁正常组织中ABCG2和P-gp蛋白的表达情况,分析其与临床病理特征的关系。结果:ABCG2主要定位于细胞膜,胞质中亦有表达,P-gp定位于细胞膜和细胞质,以细胞质为主。ABCG2和P-gp在胃癌组织中的阳性表达率分别为95.0%(57/60)和85.0%(51/60),显著高于癌旁正常组织的81.7%(49/60)和25.0%(15/60),χ2值分别为12.264和52.286,P值分别为0.007和0.000;二者在癌中的共表达率为81.7%(49/60),在表达强度上差异有统计学意义(χ2=28.381,P=0.000),且呈正相关(r=0.156),但差异无统计学意义,P=0.233;在表达程度上一致性差(Kappa=0.084),且差异无统计学意义,P=0.282;其表达均与肿瘤TNM分期、分化状态、浸润深度密切相关(P值均=0.000),与患者年龄、性别、肿瘤大小、有无淋巴结和远处转移无关,P值均>0.05。结论:ABCG2与P-gp作为胃癌检测中的敏感指标,可能成为胃癌诊断、恶性程度、肿瘤进展、耐药、疗效及预后的新指标。 OBJECTIVE:To investigate the expressions and clinical significance of ABCG2 and P-gp protein in the middle-late stage gastric cancer tissues. METHODS:The immunohistochemical method was used to detect the expressions of ABCG2 and P-gp protein in 60 cases of middle-late stage gastric cancer tissues and corresponding adjacent normal tis- sues,and their relationships with clinicopathological features were analyzed. RESULTS: ABCG2 positive stain was mainly located in cytomembrance, and could be in cytoplasmtoo, while P-gp in cytomembrance and cytoplasm, but mainly in the latter. The positive expression rate ofABCG2 and P-gp in gastric cancer tissues was 95.0%(57/60),85.0%(51/60),sig- nificantly higher than that in adjacent normal tissues of 81. 7% (49/60), 25. 0%(15/60,X2 were 12. 264 and 52. 286, P were 0. 007 and 0. 000);Their co-expression rate in the cancer was 81.7%(49/60) and the difference was statistically significant on the expression degree ( X2 = 28. 381, P = 0. 000 ), with a positive correlation ( r: 0. 156 ), but there was no statistical significance( P: 0. 233). They had a poor coherence at the expression extent (Kappa--0. 084 ), with no statisti- cal significance(P:0. 282). Their expressions were both closely correlated with the tumor TNM stage, differentiation state and invasion depth (all P=0. 000),but not related to patients'age,gender,tumor size,with or without lymph node and distant metastasis Call P〉0.05). CONCLUSION:ABCG2 and P-gp as a sensitive index in the testing of gastric canc- er, may become a new indictor for the diagnosis of gastric cancer,evaluation of malignant degree, tumor progression, drug resistance and efficacy and prognosis.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第4期273-277,共5页 Chinese Journal of Cancer Prevention and Treatment
关键词 胃肿瘤 ABG 2 P糖蛋白 多药耐药 逆转 stomach neoplasms ABCG2 P-glycoprotein multi-drug resistance reversion
  • 相关文献

参考文献18

  • 1Hu L,McArthur C,Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant[J]. Br J Cancer,2010,102(8):1276-1283.
  • 2Shi H, Lu D, Shu Y, et al. Expression of muhidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-Ⅱ and lung resistance protein in primary gastric cardiac adenocarcinoma[J]. Cancer Invest, 2008,26 (4) : 344-351.
  • 3张爱民,胡佑伦.胃癌耐药基因的表达及其在药物适配个体化治疗中的意义[J].中华实验外科杂志,2004,21(12):1485-1487. 被引量:10
  • 4金成,成炳祥,王小龙,方钿德,何海啸,胡光元.胆道恶性肿瘤组织耐药相关蛋白P-gp和GST-π表达临床意义的探讨[J].中华肿瘤防治杂志,2011,18(2):105-107. 被引量:3
  • 5胡文庆,闫曙光,王泽华,彭春伟,周英,李雁.胃癌中P-糖蛋白、多药耐药相关蛋白、肺耐药蛋白的表达及其意义[J].肿瘤研究与临床,2010,22(4):247-249. 被引量:5
  • 6Cusatis G,Sparreboom A. Pharmacogenomic importance of AB- CG2[J]. Pharmacogenomics, 2008,9 (8) .. 1005-1009.
  • 7Sun N, Sun X,Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer[J]. Cancer Chemother Pharmacol, 2010,65 (3) : 437-446.
  • 8强光辉,余德才,丁希伟,江春平.ABCG2在人肝癌细胞株中的表达及其相关功能[J].中国普外基础与临床杂志,2012,19(2):146-150. 被引量:9
  • 9Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCG2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients[J]. J Clin Oncol,2010,28(8):1287-1293.
  • 10Hu M, To KK, Mak VW, et al. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid- lowering effects of statins[J]. Expert Opin Drug Metab Toxicol, 2011,7(1):49-62.

二级参考文献82

共引文献37

同被引文献141

  • 1Ming Lu,Jing Gao, Xi-cheng Wang, Lin Shen.Expressions of Thymidylate Synthase, Thymidine Phosphorylase, Class Ⅲ β-tubulin, and Excision Repair Cross-complementing Group 1 Predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin[J].Chinese Journal of Cancer Research,2011,23(4):288-294. 被引量:22
  • 2ShengDing Bang-DongGong JianYu JunGu Hong-YuZhang Zu-BinShang QiFei PengWang Jing-DeZhu.Methylation profile of the promoter CpG islands of 14 “drug-resistance”genes in hepatocellular carcinoma[J].World Journal of Gastroenterology,2004,10(23):3433-3440. 被引量:14
  • 3Wang X K, Fu L W. Interaction of tyrosine kinase inhibitors withthe MDR-related ABC transporter proteins [ J ]. Curr Drug Metab,2010,11(7) :618 -28.
  • 4Bai F,Wang C,Lu Q, et al. Nanoparticle-mediated drug deliveryto tumor neovasculature to combat P-gp expressing multidrug resist-ant cancer[ J]. Biomaterials, 2013 ,34(26) :6163 -74.
  • 5Juliano R L, Ling V. A surface glycoprotein modulation drug per-meability in Chinese hamster ovary cell mutants [ J]. Biochim Bio-phys Acta, 1976,455(1) :152 -62.
  • 6Modrak D E,Gold D Y, Goldenberg D M. Sphingolipid targets incancer therapy [ J]. Mol Cancer Ther,2006,5(2) ;200 - 8.
  • 7Liu Y Y, Patwardhan G A, Xie P, et al. Glucosylceramide syn-thase ,a factor in modulating drug resistance,is overexpressed inmetastatic breast carcinoma[ J]. Int J Oncol,2011 ,39(2) :425 -31.
  • 8Gouaze-Andersson V,Yu J Y,Kreitenberg A J, ei al. Ceramideand glucosylceramide upregulate expression of the multidrug resist-ance gene MDR1 in cancer cells [ J ]. Biochim Biophys Acta,2007,1771(12) :1407 -17.
  • 9Liu Y Y, Gupta V, Patwardhan G A, et al. Glucosylceramide syn- thase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling [ J ]. Mol Canc- er, 2010,9 : 145.
  • 10Gerrard G, Butters T D, Ganeshaguru K, et al. Glucosylceramide synthase inhibitors sensitise CLL ceils to cytotoxic agents without re- versing P-gp functional activity[J]. EurJ Pharmacol, 2009,609(1 -3) :34 -9.

引证文献11

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部